The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function

Journal of Clinical Pharmacology

Volumn 43, Issue 2, 2003, Pages 154-162

  Skerjanec, Andrej ^a   Berenson, James ^b   Hsu, Chyi Hung ^a   Major, Pierre ^b   Miller Jr , Wilson H ^b   Ravera, Christina ^a   Schran, Horst ^a   Seaman, John ^a   Waldmeier, Felix ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Pharma AG ^*

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBON 14; CREATININE; ZOLEDRONIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; CALCIUM BLOOD LEVEL; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CREATININE CLEARANCE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; HYPERCALCEMIA; ISOTOPE LABELING; KIDNEY FUNCTION; MALE; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; PROSTATE CANCER; RIGOR; SEPSIS;

ADULT; AGED; AREA UNDER CURVE; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED;

EID: 0347708657     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002239824     Document Type: Article

References (20)

1. Diel IJ: Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol 2001;28:75-80.
2. Diel IJ, Solomayer EF, Bastert G: Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer 2000;88:3080-3088.
3. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-363.
4. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-1791.
5. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602.
6. Green JR: Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol 2001;28:4-10.
7. Green JR, Muller K, Jaeggi KA: Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-751.
8. Berenson JR: Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials. Semin Oncol 2001;28:25-34.
9. Chen T, Berenson J, Vescio R, Swift R, Goodin S, LoRusso P, et al: Pharmacokinetics and pharmacodynamics of zoledronic acid in patients with cancer and bone metastases. J Clin Pharmacol 2002; submitted for publication.
10. Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, et al: Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997;37:285-290.
11. Mitchell DY, St Peter JV, Eusebio RA, Pallone KA, Kelly SC, Russell DA, et al: Effect of renal function on risedronate pharmacokinetics after a single oral dose. Br J Clin Pharmacol 2000;49;215-222.
12. Lin JH: Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75-85.
13. Adami S, Zamberlan N: Adverse effects of bisphosphonates: a comparative review. Drug Saf 1996;14:158-170.
14. Alden CL, Parker RD, Eastman DF: Development of an acute model for the study of chloromethanediphosphonate nephrotoxicity. Toxicol Pathol 1989;17:27-32.
15. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F: Renal failure associated with intravenous diphosphonates. Lancet 1983;1:471.
16. Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG: Effects of intravenous diphosphonates on renal function. Lancet 1983;1:1328.
17. Dumon JC, Magritte A, Body JJ: Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner 1991;15:257-266.
18. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
19. Cancer Therapy Evaluation Program: Common Toxicity Criteria. Version 2.0. DCTD, NCI, NIH, DHHS. March 1998 (Publish date: April 1999).
20. Mitchell DY, Heise MA, Pallone KA, Clay ME, Nesbitt JD, Russell DA, et al: The effect of dosing regimen on the pharmacokinetics of risedronate. Br J Clin Pharmacol 1999;48:536-542.